Company Overview and News

Mudajaya hits new milestone for India power plant project

2018-08-27 malaymail
KUALA LUMPUR, Aug 27 — Mudajaya Group Bhd has announced the successful commissioning and commercial operation of the third unit of its power plant project in India.
5085 BSMAF 1818

Third unit of Mudajaya’s India power plant achieves commercial operations

2018-08-27 theedgemarkets
KUALA LUMPUR (Aug 27): The third unit of Mudajaya Group Bhd’s coal-fired thermal power plant in India’s Chhattisgarh state has achieved its commercial operation date (COD).
5085 BSMAF 1818

Mudajaya’s tower contract terminated

“We wish to announce that Mudajaya had on Aug 14 received a letter dated Aug 13 from the KLIA Consortium informing that the contract for the project had been terminated with effect from Aug 13,” Mudajaya told Bursa Malaysia.
5085 BSMAF 1818

Public Bank, Press Metal, KLCCP, CIMB Group, PetChem, PetGas, Sam Engineering, Oriental Interest, Scientex, Mudajaya and MK Land

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): Based on corporate announcements and news flow today, stocks in focus tomorrow may include: Public Bank Bhd, Press Metal Aluminium Holdings Bhd, KLCCP Stapled Group, CIMB Group Holdings Bhd, Petronas Chemicals Group Bhd, Petronas Gas Bhd, Sam Engineering & Equipment (M) Bhd, Oriental Interest Bhd, Scientex Bhd, Mudajaya Group Bhd and MK Land Holdings Bhd.
PBLOF 5183 PECGF 5085 1295 6033 8893 CIMDF 1023 PNADF 8869 5827 PNAGF

Mudajaya’s RM118.6m Sungai Buloh office tower contract terminated

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): Mudajaya Group Bhd (MCB) said the RM118.6 million contract it was offered to build an office complex called Hevea Tower in Sungai Buloh, Selangor, has been terminated.

Report: New contractor claims may raise LRT3 cost despite govt’s tweaks

2018-07-24 malaymail
KUALA LUMPUR, July 24 — The price tag for the third line of the Light Rail Transit (LRT3) may rise after all despite the new Pakatan Harapan (PH) government’s recent move to shave the construction costs by a whopping RM15.02 billion.
3204 5226 1800 5263 9679 CMEGF 5085

India beckons, but business challenges aplenty

2018-06-20 theedgemarkets
WITH a market of 1.2 billion people and a growing middle class, it is hard for anyone to ignore the economic potential of India. Malaysian companies too have been looking at the country to expand their markets.
6888 7366 IDEA ICLQY AXXTF 5085 532822

The Week Ahead: Eyes on Trump-Kim rendezvous, FOMC hike, full Cabinet line-up and World Cup 2018

2018-06-11 theedgemarkets
The world will be watching two of the greatest shows this week — the momentous meeting between US President Donald Trump and North Korean leader Kim Jong-un at the Capella Hotel in Singapore on June 12, and the kick-off of the 2018 Fifa World Cup in Moscow on Thursday, just ahead of the Hari Raya celebrations on Friday.
9717 5216 1201 3921 0091 CPICQ FUTR 5085 0151 8311 0152 LIIHF

Mudajaya unit secures RM90mil Islamic financing facilities

2018-03-20 - 1
PETALING JAYA: Construction firm Mudajaya Group Bhd ’s wholly owned subsidiary, Mudajaya Corp Bhd, has secured RM90mil worth of Islamic financing facilities from Kuwait Finance House (M) Bhd.
5085 BSMAF 1818

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...